People are likely missing the significance here with our CORE-NK platform. The NK-cells are genetically modified but not engineered like CAR-NK cells. The cost of manufacturing them and getting the tech into the clinic is minimal AND other biotech companies are currently trialing it with their novel drugs and frontline drugs! Commercialisation or, at least, monetisation via out-licensing deals, could be closer than we may think.
For both targeted therapies and immunotherapies to have lasting effects they need the help of robust immune systems to carry on the work of preventing relapse. CORE-NK could be just what the doctor orders!
People are likely missing the significance here with our CORE-NK...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $69.79K | 17.44M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 40 | 26298938 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 9548289 | 12 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |